CA-FUNGIBLE
7.6.2022 15:03:34 CEST | Business Wire | Press release
Fungible Inc., the dynamic composable infrastructure company, today announced a new release of Fungible Storage Cluster® (FSC) 4.1, providing support for VMware vSphere® environments requiring high-performance.
Virtual machines provide unparalleled flexibility in managing complex and changing compute environments. Workloads running in virtualized environments can have varied storage requirements. For demanding workloads, Fungible’s high-performance all-flash array based on NVMe/TCP is now certified for vSphere and available for VMware virtualized environments. The latest release (4.1) will now enable customers to experience the superior manageability of vSphere combined with the high performance of Fungible’s Storage Cluster.
"NVMe/TCP enables vSphere customers to accelerate their storage performance while leveraging existing investments and lowering complexity,” said Marc Fleischmann, Cloud CTO, VMware, “Through collaboration with innovative companies such as Fungible, VMware continues to build a world-class ecosystem of technology partners that offer our customers flexibility and choice to meet their business requirements.”
Customers can plug FSC storage into their ESXi servers with NVMe/TCP and get what appears to be local storage. The resulting performance is nearly identical to local storage even though it is a shared resource providing economic benefits to match the performance benefits.
“VMware vSphere is the virtualization infrastructure of choice for a variety of mission-critical, performance-sensitive workloads in the data center,” said Eric Burgener, Research Vice President, Infrastructure Systems, Platforms and Technologies at IDC. “As IT organizations deploy more workloads that require accelerated compute and storage, the use of composable, disaggregated infrastructure (CDI) like that available from Fungible will be deployed more often to enable the more efficient use of these types of resources in VMware environments. IDC expects that the CDI market overall will top $4.8 billion by 2025.”
“VMware has long led the drive to improve flexibility and utilization of data center infrastructure. Now with the latest release of our vSphere certified Fungible Storage Cluster, VMware users can further enhance their ability to tune demanding workloads to get the utmost performance and flexibility,” said Pradeep Sindhu, Co-Founder and CDO of Fungible. “Trade-offs of flexibility versus performance are no longer required. Pairing VMware with NVMe/TCP for storage access with our DPU-powered Storage Cluster allows VMware customers to address the performance requirements of today's modern applications.”
With FSC, vSphere users may also see storage cost savings since FSC’s erasure coding provides robust data protection which can be less expensive than traditional RF1 or RF2 replication. Additionally, Fungible’s composable data infrastructure provides flexibility to compose storage to meet current needs and recompose it to adapt to changing needs providing outstanding investment protection.
To learn more about the new FSC 4.1 and the VMware vSphere certification and how you can get more value and performance from your VMware vSphere resources click here or contact sales@fungible.com .
About Fungible:
Silicon Valley-based Fungible, the world’s premier dynamic composable infrastructure company, creates solutions to cloudify the world’s data centers by utilizing the Fungible DPU™ to connect CPUs, GPUs, and storage via NVMe/TCP over standard IP/Ethernet networks. Fungible aims to revolutionize the performance, economics, reliability and security of scale-out data centers. Visit Fungible to learn more. Follow us on Twitter and LinkedIn .
Fungible and Fungible FSC are registered trademarks of Fungible, Inc. VMware and vSphere are registered trademarks or trademarks of VMware, Inc. in the United States, and other jurisdictions. This article may contain hyperlinks to non-VMware websites that are created and maintained by third parties who are solely responsible for the content on such websites.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220607005155/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
RS2 Launches “Beyond by RS2” to Power the Next Generation of European Fintech17.3.2026 08:00:00 CET | Press release
RS2, a Tier-1 global provider of payment processing infrastructure and technology solutions, today announced the launch of Beyond by RS2, a new digital payments brand designed to help fintech companies, platforms, and payment providers rapidly launch card issuing and payment acceptance services across Europe. Built on RS2’s globally proven BankWORKS platform, Beyond by RS2 offers fintechs a comprehensive sponsored issuer and acquiring program, enabling partners to issue cards and process payments without needing their own banking license or direct card scheme membership. The program leverages RS2’s Electronic Money Institution (EMI) license in Germany and its principal membership with Visa and Mastercard, allowing fintech partners to operate under RS2’s regulated infrastructure while maintaining their own customer experience and brand. “Beyond by RS2 represents a major step in our strategy to enable innovation in payments,” said Radi El Haj, CEO, RS2. “Fintechs today want to build powe
Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G Nfl Blood Assay17.3.2026 07:00:00 CET | Press release
H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter “Fujirebio”) today announced that Fujirebio Europe N.V. has obtained a CE Certificate of the Lumipulse G NfL Blood assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows for the quantitative measurement of Neurofilament light chain (NfL) in plasma and serum. “While our assay menu already features many powerful disease-specific biomarkers, NfL marks a major breakthrough: our first CE-marked blood test that empowers clinicians with insights across a wide range of neurological disorders,” said Christiaan De Wilde, CEO at Fujirebio Europe N.V. “We are excited to bring this test to our customers, further expanding our comprehensive portfolio of fully automated neurological disease testing solutions on the LUMIPULSE G platform. We continue to partner with organizations and clinical experts across the wor
H2SITE Appoints Javier Cavada as New Chairman of the Board of Directors17.3.2026 07:00:00 CET | Press release
H2SITE, a technology company delivering hydrogen production and separation solutions, announces the appointment of Javier Cavada as the new Chairman of the Board of Directors. Javier joins H2SITE at a strategic phase of accelerated industrial deployment and scale-up of its hydrogen solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316654723/en/ With more than 25 years of international leadership in the energy and industrial sectors, Javier brings extensive experience in industrialising complex technologies, building high-performance organisations, and scaling large-scale energy platforms. He currently serves as President and Chief Executive Officer of Mitsubishi Power EMEA. His track record also includes serving as CEO and President of Highview Power, as well as spending 17 years at Wärtsilä Corporation, where he held senior executive roles including President of the Energy division and a member of the global Exec
AMWC 2026: Galderma Showcases Category‑leading Innovation With a Comprehensive Portfolio and Holistic, Future‑focused Aesthetic Strategies17.3.2026 07:00:00 CET | Press release
Galderma will present nine posters spanning its full aesthetics portfolio at AMWC 2026, highlighting the regenerative benefits of Sculptra®, the long-lasting efficacy of Restylane®, and the advanced clinical performance of Relfydess® (RelabotulinumtoxinA) 1-9 The data reinforce Galderma’s future-focused approach to innovation, addressing emerging patient needs from menopause‑related skin changes to rising interest in body injectables and regenerative treatments A series of symposia and Masterclasses will further highlight Galderma’s leadership in aesthetics, showcasing how the portfolio supports complex patient profiles and evolving global trends Galderma (SIX: GALD) will present nine abstracts at the Aesthetic & Anti‑Aging Medicine (AMWC) World Congress 2026 in Monaco, showcasing innovative and robust scientific data across its aesthetics portfolio, alongside three symposia, and multiple Masterclasses and Meet‑the‑Expert sessions, all highlighting the expanding benefits of Sculptra, R
Miro Announces Asia Hub in Singapore to Accelerate Growth Across the Region and Bring AI Collaboration to New Markets17.3.2026 02:00:00 CET | Press release
AI Innovation Workspace perfectly placed to help organisations maximise AI investment and accelerate innovation Miro®, the AI Innovation Workspace for teams, today announced plans to expand its operations in Asia, supporting organisations across the region in their AI transformation journey. Miro is investing in people, resources, and infrastructure as it targets growth in key markets, including Singapore, India, South Korea, and other Southeast Asia countries. As the global innovation centre of gravity shifts toward Asia – where R&D spending reached 45% of global investment in 2024 – the organisations leading this charge need tools and platforms built for the complexity and pace of modern innovation and collaboration. Miro's AI-powered innovation workspace is uniquely positioned to support this moment. Miro gives organisations the shared context layer they need to move from insight to execution faster than ever before. For Asia's most ambitious innovators, where speed-to-market and cr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom